Regeneron monoclonal antibody gets WHO recommendation for Ebola
Sean Gallup/Getty Images News


Announcing the publication of the first guidelines on treatments for Ebola on Friday, the World Health Organization said that it recommends monoclonal antibodies Inmazeb and Ebanga for the viral disease. The drugs were developed by Regeneron (NASDAQ:REGN) and Ridgeback Biotherapeutics, respectively.

The decision follows the findings of randomized clinical trials designed to evaluate the therapeutics in Ebola, a severe and often fatal illness caused by the Ebola virus.
The trials were conducted during the disease outbreaks, and the largest trial got underway in the Democratic Republic of the Congo, the WHO said.
In addition, the WHO recommended against the use of monoclonal antibody ZMapp and antiviral infusion remdesivir for Ebola.
ZMapp is developed by San Diego-based drugmaker Mapp Biopharmaceutical, Inc.
Remdesivir, marketed by Gilead (GILD) as Veklury for COVID-19, added $5.6B in sales for the company in 2021, indicating ~98% YoY growth.